Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency

Keyphrases

• Non-alcoholic Fatty Liver Disease (NAFLD) 100%
• Gut Microbiota 100%
• Butyrate 100%
• Estrogen Deficiency 100%
• Premenopause 100%
• Short-chain Fatty Acids 33%
• OVX Mice 33%
• Estrogen 25%
• Postmenopausal Women 25%
• Antimicrobial Peptides 16%
• Hepatic Steatosis 8%
• Gene-deficient Mice 8%
• Lipid Metabolism 8%
• Liver Steatosis 8%
• Clinical Treatment 8%
• Clinical Significance 8%
• New Drug Targets 8%
• Microbiota 8%
• Fecal Microbiota Transplantation 8%
• Ovariectomy 8%
• Estrogen Level 8%
• Serum Triglycerides 8%
• Defensin 8%
• Peptide Production 8%
• Zonula occludens-1 (ZO-1) 8%
• Abdominal Fat 8%
• Gut Microbiota Composition 8%
• Reg3 8%
• VLDLR 8%
• Abnormal Lipid Metabolism 8%
• Peptide Lipids 8%
• Intestinal Tight Junction 8%
• Clinical Prevention 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Nonalcoholic Fatty Liver 100%
• Intestine Flora 100%
• Butyrate 100%
• Estrogen Deficiency 100%
• Estrogen 33%
• Short Chain Fatty Acid 25%
• Fatty Liver 16%
• Peroxisome Proliferator Activated Receptor 16%
• Lipid 16%
• Polypeptide Antibiotic Agent 16%
• Deterioration 8%
• Microflora 8%
• Triacylglycerol 8%
• Feces microflora 8%
• Diseases 8%

Immunology and Microbiology

• Intestine Flora 100%
• Premenopause 100%
• Short Chain Fatty Acid 60%
• Lipid Metabolism 40%
• Antimicrobial Peptides 40%
• Metabolite 20%
• Upregulation 20%
• Downregulation 20%
• Microflora 20%
• Body Weight 20%
• Tight Junction 20%
• Triacylglycerol Blood Level 20%
• Postmenopause 20%
• Abdominal Fat 20%
• Feces microflora 20%
• Therapeutic Target 20%